As we reach the end of 2025, the Indica Labs team extends our sincere thanks to the customers and collaborators who helped make this year one of remarkable innovation, growth, and scientific achievement.
Looking Back: Reviewing 2025 at Indica Labs Read More »
19 February 2026 | Learn the fundamentals of the HALO GraphQL API and how to design, develop, and implement time-saving automations
Designing and Developing Automated Solutions Using the HALO GraphQL API Read More »
Download this application note to learn about the tools provided by the HALO Spatial Analysis module and how they are used to identify proximity and relative spatial distribution of cells and objects.
Spatial Analysis Application Note Read More »
22 January 2026 | Learn how HALO and HALO AI are helping expand our understanding of immune regulation by different subtypes of cancer-associated fibroblasts!
Highly multiplexed imaging reveals CAF-immune cell niches in cutaneous carcinomas Read More »
As scientists work to continue unraveling the structural, cellular, and molecular complexities of the brain and its diseases, the characteristics of this unique tissue pose significant challenges to traditional histological analysis.
Advancing Neuroscience Research with HALO® and HALO AI Read More »
We’re excited to announce the launch of the newly updated Muscle Fiber BF and Muscle Fiber FL modules supporting AI nuclear segmentation, AI membrane segmentation, interactive markups, and new output metrics..
Check out this collaborative poster to learn about a streamlined triplex chromogenic workflow leveraging HALO and HALO AI for analysis of slides assayed with Leica Biosystems’ ChromoPlex III Triple Detection RUO.
Chromogenic triplex characterization of breast and gastrointestinal cancers Read More »
Updated Muscle Fiber BF and FL modules are now available! Submit the form below to request your upgrade. How it works: Following submission of an
Updated Muscle Fiber BF and FL modules are now available! Read More »
Antibody-drug conjugates (ADC) represent one of the most promising classes of next-generation cancer therapeutics, combining antibody-based targeting with the potency of chemotherapy.
